4/A: Artivion SVP Marshall Stanton Corrects Stock Transaction Reporting in Amended SEC Filing
SEC Filing (Form 4/A)
Marshall Stanton, SVP of Clinical & MD Affairs at Artivion, Inc., files an amendment to a previous SEC Form 4 to correct the number of shares sold to cover tax withholding obligations.
Summary
- Marshall Stanton, SVP of Clinical & MD Affairs at Artivion, Inc., filed an amended SEC Form 4 on March 14, 2024, to correct errors in the number of shares sold on February 26, 2024, to cover tax withholding obligations.
- The original filing incorrectly reported the sale of 1,600 shares and 1,448 shares in two separate transactions, while the corrected numbers are 1,576 and 1,431 shares, respectively.
- The amendment reflects adjustments to the number of shares beneficially owned following these corrected transactions.
- The transactions involved the vesting of performance stock units granted on February 22, 2023, with portions of the units being issued on February 23, 2024.
- Future vesting of remaining shares from the February 2023 grant is scheduled for February 22, 2025, and February 22, 2026, contingent upon continued employment.
Sentiment
Score: 7
Explanation: The document is a routine correction of an administrative error in an SEC filing. It doesn't indicate any fundamental issues with the company, but the initial error is a minor negative.
Positives
- The amendment ensures accurate reporting of stock transactions, promoting transparency.
Negatives
- The need for an amendment indicates an initial administrative error in reporting.
Risks
- While the amendment corrects a minor error, repeated inaccuracies in SEC filings could raise concerns about internal controls.
Future Outlook
Remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date.
Industry Context
SEC Form 4 filings are routine disclosures for company insiders and provide transparency into their trading activities. Amendments are not uncommon and often address minor administrative errors.
Stakeholder Impact
- The correction ensures shareholders have accurate information regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 02/22/2023 | Date of original performance stock unit grant. |
| 02/23/2024 | Date when 100% and 50% of performance stock units were issued. |
| 02/26/2024 | Date of the stock sales to cover tax withholding obligations. |
| 02/28/2024 | Date of original filing. |
| 02/22/2025 | Scheduled vesting date for 25% of remaining shares from the Feb 2023 grant. |
| 02/22/2026 | Scheduled vesting date for 25% of remaining shares from the Feb 2023 grant. |
| 03/14/2024 | Date of the amended SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.